Australia markets open in 36 minutes

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
96.44-0.77 (-0.79%)
At close: 04:00PM EDT
96.44 0.00 (0.00%)
After hours: 05:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 9.10B
Enterprise value 8.38B
Trailing P/E 60.42
Forward P/E 30.03
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.26
Price/book (mrq)5.33
Enterprise value/revenue 5.63
Enterprise value/EBITDA 35.41

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 32.53%
S&P500 52-week change 3-12.41%
52-week high 3129.29
52-week low 375.25
50-day moving average 3104.25
200-day moving average 3106.76

Share statistics

Avg vol (3-month) 3810.56k
Avg vol (10-day) 3765.72k
Shares outstanding 596.59M
Implied shares outstanding 6N/A
Float 895.3M
% held by insiders 10.97%
% held by institutions 196.19%
Shares short (27 Feb 2023) 42.54M
Short ratio (27 Feb 2023) 42.78
Short % of float (27 Feb 2023) 43.02%
Short % of shares outstanding (27 Feb 2023) 42.63%
Shares short (prior month 30 Jan 2023) 42.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 428 Dec 1995
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin 10.38%
Operating margin (ttm)16.73%

Management effectiveness

Return on assets (ttm)7.01%
Return on equity (ttm)10.03%

Income statement

Revenue (ttm)1.49B
Revenue per share (ttm)15.54
Quarterly revenue growth (yoy)32.10%
Gross profit (ttm)1B
Net income avi to common (ttm)154.5M
Diluted EPS (ttm)1.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)989.3M
Total cash per share (mrq)10.24
Total debt (mrq)280.3M
Total debt/equity (mrq)16.41
Current ratio (mrq)2.70
Book value per share (mrq)17.70

Cash flow statement

Operating cash flow (ttm)339.4M
Levered free cash flow (ttm)226.99M